|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 362.60 USD | -1.47% |
|
-3.07% | +10.80% |
| Jul. 08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| Jul. 08 | Morgan Stanley Adjusts Price Target Amgen to $333 From $340, Maintains Equalweight Rating | MT |
| Market Cap | 199B 174B 160B 148B 281B 18,957B 286B 1,919B 752B 9,309B 746B 729B 32,246B | P/E 2026 * |
24.1x | P/E 2027 * | 22.1x |
|---|---|---|---|---|---|
| Enterprise Value | 241B 211B 194B 180B 341B 22,973B 347B 2,325B 911B 11,281B 904B 884B 39,077B | EV / Sales 2026 * |
6.37x | EV / Sales 2027 * | 6.08x |
| Free-Float |
99.78% | Yield 2026 * |
2.74% | Yield 2027 * | 2.9% |
Last Transcript: Amgen Inc.
| 1 day | -1.21% | ||
| 1 week | -3.10% | ||
| Current month | +0.12% | ||
| 1 month | +5.22% | ||
| 3 months | +1.96% | ||
| 6 months | +11.18% | ||
| Current year | +10.77% |
| 1 week | 359.47 |  | 375.25 |
| 1 month | 334.05 | | 375.25 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.61 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24% | -3.10% | +22.27% | +61.33% | 199B | |
| -0.04% | +0.06% | +54.35% | +168.03% | 1,084B | |
| -1.33% | -1.26% | +66.20% | +62.83% | 634B | |
| -1.17% | -4.53% | +30.75% | +85.33% | 447B | |
| +0.18% | -1.76% | +29.04% | +26.48% | 330B | |
| -6.22% | -8.14% | +28.87% | +31.18% | 295B | |
| -1.27% | -2.91% | +27.42% | +44.91% | 285B | |
| -0.93% | -3.57% | -27.74% | -39.70% | 218B | |
| -1.32% | +1.84% | +18.06% | +76.63% | 169B | |
| +0.85% | -0.37% | -5.20% | -32.09% | 137B | |
| Average | -1.26% | +2.34% | +24.40% | +48.49% | 379.69B | |
| Weighted average by Cap. | -1.09% | +2.42% | +37.20% | +79.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.77B 33.04B 30.47B 28.19B 53.52B 3,606B 54.41B 365B 143B 1,771B 142B 139B 6,133B | 38.7B 33.86B 31.22B 28.89B 54.83B 3,694B 55.75B 374B 147B 1,814B 145B 142B 6,284B |
| Net income | 8.23B 7.2B 6.64B 6.14B 11.66B 786B 11.86B 79.52B 31.17B 386B 30.9B 30.23B 1,336B | 8.86B 7.75B 7.15B 6.62B 12.56B 846B 12.77B 85.64B 33.57B 416B 33.28B 32.56B 1,439B |
| Net Debt | 42.07B 36.8B 33.94B 31.4B 59.6B 4,016B 60.6B 406B 159B 1,972B 158B 155B 6,830B | 36.52B 31.94B 29.46B 27.26B 51.73B 3,485B 52.6B 353B 138B 1,712B 137B 134B 5,929B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-09 | $362.45 | -1.51% | 682,006 |
| 26-07-08 | $367.99 | -0.03% | 1,758,925 |
| 26-07-07 | $368.10 | +0.45% | 1,983,666 |
| 26-07-06 | $366.44 | -2.06% | 2,838,007 |
| 26-07-02 | $374.15 | +3.55% | 2,487,837 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
